Rose, HDG, I am running out of messages for the day so I will try to respond to you both at the same time. The Hikma lawyers can't claim that they are the good guys here gv is apparently more expensive than V. If Hikma looses in court an ANDA for any version of gv becomes a moot point. The ANDA gives a generic company the ability to enter the market by FDA. If the court is going to determine that being in the market with the FDA approved label is infringing, what value does the approval have? That is analogous to getting permission to walk into a mine field. The fact is that 12 average people on a jury are unpredictable. I doubt that Hikma would want to take this to a conclusion. It is my belief that a victory against Hikma would prevent any other generic companies from entering the US market.
Sleven,
News 
Market Data 
Discover 
